Jiang Yan, Luo Baolin, Lu Wen, Chen Yaqin, Peng Yanchun, Chen Liangwan, Lin Yanjuan
School of Nursing, Fujian Medical University, Fuzhou, Fujian, People's Republic of China.
Department of Nursing, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China.
J Inflamm Res. 2024 Oct 3;17:7057-7067. doi: 10.2147/JIR.S481515. eCollection 2024.
The Aggregate Index of Systemic Inflammation (AISI) has emerged as a novel marker for inflammation and prognosis, but its role in patients with acute myocardial infarction has not been studied. Therefore, this study aimed to investigate the impact of different AISI levels on the clinical outcomes of patients with acute myocardial infarction.
This study was a retrospective study, including 1044 patients with acute myocardial infarction (AMI) who were treated at the Fujian Medical University Affiliated Union Hospital, China from May 2017 to December 2022. The patients were divided into high and low AISI groups based on the median value (Q1 Group, ≤ 416.15, n=522; Q2 Group, ≥ 416.16, n=522), and the differences in baseline characteristics and clinical outcomes between the two groups were analyzed. The primary outcome included major adverse cardiovascular and cerebrovascular events (MACCEs), while the secondary outcomes included contrast-induced nephropathy (CIN) risk and all-cause rehospitalization rate.
The findings of the single-factor analysis suggest that a significant association between high AISI levels and the occurrence of MACCEs in AMI patients. After adjusting for confounding factors, the results indicated that compared to Q1, patients in the Q2 group had a higher risk of all-cause mortality [adjusted odds ratio (aOR) 4.64; 95% CI 1.37-15.72; =0.032], new-onset atrial fibrillation (aOR 1.75; 95% CI 1.02-3.00; =0.047), and CIN (aOR 1.75; 95% CI 1.02-3.01; =0.043), with all differences being statistically significant.
In the population of AMI patients, an elevated AISI level is significantly associated with an increased risk of cardiovascular death and can serve as an early marker for adverse prognosis.
全身炎症综合指数（AISI）已成为一种新的炎症和预后标志物，但其在急性心肌梗死患者中的作用尚未得到研究。因此，本研究旨在探讨不同AISI水平对急性心肌梗死患者临床结局的影响。
本研究为回顾性研究，纳入2017年5月至2022年12月在中国福建医科大学附属协和医院接受治疗的1044例急性心肌梗死（AMI）患者。根据中位数将患者分为AISI高水平组和低水平组（Q1组，≤416.15，n = 522；Q2组，≥416.16，n = 522），分析两组患者的基线特征和临床结局差异。主要结局包括主要不良心血管和脑血管事件（MACCEs），次要结局包括对比剂肾病（CIN）风险和全因再住院率。
单因素分析结果表明，AISI高水平与AMI患者发生MACCEs之间存在显著关联。在调整混杂因素后，结果显示，与Q1组相比，Q2组患者全因死亡风险更高[调整后的优势比（aOR）4.64；95%置信区间1.37 - 15.72；P = 0.032]、新发房颤（aOR 1.75；95%置信区间1.02 - 3.00；P = 0.047）和CIN（aOR 1.75；95%置信区间1.02 - 3.01；P = 0.043），所有差异均具有统计学意义。
在AMI患者群体中，AISI水平升高与心血管死亡风险增加显著相关，可作为不良预后的早期标志物。
